DDC-AS1: A Promising Drug Target / Biomarker (G100129427)

Target Name: DDC-AS1

NCBI ID: G100129427

DDC-AS1

Other Name(s): DDC antisense RNA 1

DDC-AS1: A Promising Drug Target / Biomarker

Drug discovery is an ongoing process that aims to identify and develop new therapeutic compounds to treat various diseases. One of the significant advances in drug discovery is the identification of potential drug targets, which are molecules that can be targeted with drugs to induce therapeutic effects. One of the promising drug targets in recent years is DDC-AS1, which is a protein that is expressed in various tissues and plays a crucial role in many biological processes. In this article, we will discuss DDC-AS1 in detail, including its structure, function, and potential as a drug target.

Structure and Function

DDC-AS1 is a member of the Asparagine-Sulfate Transporter (AST) family, which is a subfamily of the protein transporter superfamily. ASTs are known for their ability to transport various molecules across cell membranes, including drugs, toxins, and ions. DDC-AS1 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, brain, and kidney. It is primarily localized to the endoplasmic reticulum (ER), where it is involved in the transport of Asparagine, a precursor molecule for the production of proteins and nucleic acids.

DDC-AS1 functions as a drug target by participating in the delivery of various molecules across the cell membrane. It has been shown to play a crucial role in the transport of various drugs, including statins, which are used to treat hyperlipidemia. In addition to its role in drug delivery, DDC-AS1 is also involved in the regulation of cellular signaling pathways. For instance, it has been shown to be involved in the regulation of the T-cell receptor (TCR) signaling pathway, which is critical for the development and activation of T cells.

DDC-AS1 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis. For example, it has been shown to be involved in the regulation of the production and degradation of extracellular matrix (ECM) components, such as collagen and elastin. These molecules are essential for maintaining the structural integrity of tissues and are involved in many physiological processes, including joint mobility and tissue repair.

Potential as a Drug Target

DDC-AS1 has been identified as a potential drug target due to its involvement in various cellular processes that are important for human health. The use of drugs that target DDC-AS1 has the potential to treat a wide range of diseases, including cardiovascular disease, neurodegenerative diseases, and autoimmune diseases.

One of the significant advantages of targeting DDC-AS1 is its potential to be a once-daily drug. DDC-AS1 is expressed in various tissues and is primarily localized to the ER, which means that it is not targeted by most drugs. By expressing DDC-AS1 in a genetically modified cell line, it is possible to create a transgenic cell that expresses DDC-AS1, which can then be used as a drug target. This approach has the potential to improve the safety and efficacy of drugs by reducing the dose required and increasing the amount of drug available in the body.

Another advantage of targeting DDC-AS1 is its potential to be a once-weekly drug. DDC-AS1 is expressed in various tissues and has been shown to be involved in the regulation of cellular signaling pathways that are important for many physiological processes. By expressing DDC-AS1 in a genetically modified cell line, it is possible to create a transgenic cell that expresses DDC-AS1, which can then be used as a drug target. This approach has the potential to improve the safety and efficacy of drugs by reducing the dose required and increasing the amount of drug available in the body.

Despite the potential benefits of targeting DDC-AS1, there are also potential drawbacks to consider. One of the significant challenges is the development of genetic modified organisms (GMOs), which can be used to create transgenic cells that express DDC-AS1. The development of GMOs requires the use of highly regulated techniques and can be a

Protein Name: DDC Antisense RNA 1

The "DDC-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDC-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets